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REGULAR ARTICLE

Expression proﬁling of snoRNAs in normal hematopoiesis and AML
Wayne A. Warner,1,* David H. Spencer,1-3,* Maria Trissal,1 Brian S. White,1,2 Nichole Helton,1 Timothy J. Ley,1-3 and Daniel C. Link1,3
1

Division of Oncology, 2McDonnell Genome Institute, School of Medicine, and 3Siteman Cancer Center, Washington University, St. Louis, MO

Key Points

• A subset of snoRNAs
is expressed in a developmental- and
lineage-specific manner during human
hematopoiesis.
• Neither host gene expression nor alternative
splicing accounted for
the observed differential
expression of snoRNAs
in a subset of AML.

Small nucleolar RNAs (snoRNAs) are noncoding RNAs that contribute to ribosome biogenesis
and RNA splicing by modifying ribosomal RNA and spliceosome RNAs, respectively. We
optimized a next-generation sequencing approach and a custom analysis pipeline to
identify and quantify expression of snoRNAs in acute myeloid leukemia (AML) and normal
hematopoietic cell populations. We show that snoRNAs are expressed in a lineage- and
development-speciﬁc fashion during hematopoiesis. The most striking examples involve
snoRNAs located in 2 imprinted loci, which are highly expressed in hematopoietic progenitors
and downregulated during myeloid differentiation. Although most snoRNAs are expressed
at similar levels in AML cells compared with CD341, a subset of snoRNAs showed
consistent differential expression, with the great majority of these being decreased in the
AML samples. Analysis of host gene expression, splicing patterns, and whole-genome
sequence data for mutational events did not identify transcriptional patterns or genetic
alterations that account for these expression differences. These data provide a
comprehensive analysis of the snoRNA transcriptome in normal and leukemic cells and
should be helpful in the design of studies to deﬁne the contribution of snoRNAs to
normal and malignant hematopoiesis.

Introduction
There has been increasing interest in the contribution of the noncoding transcriptome to the regulation
of normal and malignant hematopoiesis. Noncoding RNA (ncRNA) species are classified into 2 groups
based on their sizes. Long noncoding RNAs (lncRNAs) are .200 nucleotides, and they are expressed in
a lineage-specific fashion in hematopoiesis.1 Recent studies have implicated lncRNAs in hematopoietic
lineage commitment and control of self-renewal.1 Small noncoding RNAs (sncRNAs) are ,200
nucleotides and include a heterogeneous group of RNA species. Best characterized are microRNAs
(miRNAs), which are 19-26 nucleotide RNAs that repress translation of target RNAs by targeting them
to the RNA-induced silencing complex. MicroRNAs are also expressed in a lineage-specific fashion and
have been shown to play key roles in the regulation of hematopoiesis.2-4 Other sncRNAs include small
nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), small interfering RNAs, and Piwi-interacting
RNAs. With some exceptions, the expression of these other sncRNAs in hematopoietic cells and their
contribution to the regulation of hematopoiesis are not well characterized.
snoRNAs are a subset of sncRNAs that are involved in the posttranscriptional modification of ribosomal
RNAs (rRNAs) and snRNAs. These modifications are critical for a variety of cellular processes, including
ribosomal biogenesis and splicing of RNAs. Classification of snoRNA species is based on the presence
of highly conserved sequence elements that define 3 snoRNA families: H/ACA box (SNORAs), C/D
box (SNORDs), or small Cajal body–specific RNAs (scaRNAs). H/ACA and CD box snoRNAs
target specific ncRNA species with base pair complementarity for site-specific pseudouridylation5 or
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2’-O-methylation,6 respectively. scaRNAs localize to RNA-containing
Cajal bodies and are responsible for the methylation and pseudouridylation of spliceosomal RNAs U1, U2, U4, U5, and U12. There are
also orphan snoRNAs, which lack known complementarity to rRNAs or
snRNAs and therefore largely have unknown functions. Recent studies
have suggested an expanded role for snoRNAs beyond ribosomal
biogenesis and modifications to snRNA. For example, emerging data
suggest that snoRNAs may contribute to alternative splicing,7 regulation
of chromatin structure,8 metabolism,9 and neoplastic transformation.10
The contribution of snoRNAs to the regulation of normal and malignant
hematopoiesis is largely unknown. Chu et al reported that overexpression of the H/ACA box snoRNA ACA11 in t(4;14)-associated
multiple myeloma contributes to myeloma cell proliferation and
resistance to chemotherapy.11 Several groups have reported marked
increased expression of snoRNAs contained in the DLK-DIO3 locus in
acute promyelocytic leukemia, although their contribution to leukemogenesis is unknown.12-14 The lack of a method to accurately and
comprehensively assess snoRNA expression has limited research in
this area. Array-based methods only interrogate a subset of snoRNAs
and cannot distinguish between mature and precursor snoRNAs.15,16
To avoid sequencing very abundant rRNAs and transfer RNAs
(tRNAs), most next-generation sequencing approaches to interrogate
the transcriptome have focused on longer (.200 nucleotide) or very
short (17-26 nucleotide) RNA species. Thus, there is a gap in current
transcriptome sequencing that includes most snoRNAs. To address
this gap, we developed a next-generation sequencing approach
optimized to interrogate sncRNAs, including snoRNAs. We show that
snoRNAs are expressed in a lineage- and development-specific
fashion in human hematopoiesis with a subset of snoRNAs that show
consistent differential expression in acute myeloid leukemia (AML). We
further show that expression of snoRNAs does not correlate with
expression or splicing of host genes, suggesting that other factors are
determining cellular levels of mature snoRNAs.

Materials and methods
Fluorescence-activated cell sorting of
hematopoietic populations
Bone marrow aspirate samples were obtained from normal healthy
donors after obtaining informed consent (institutional review board
approval Washington University Human Studies Committee #01-1014).
Samples were processed via ammonium–chloride–potassium red cell
lysis, washed once in phosphate-buffered saline, and then stained for
flow cytometry using the following antibodies: CD34-phycoerythrin (PE)
(PE-pool, Beckman Coulter, IM1459U), CD14-allophycocyanin (BD
Biosciences, clone M5E2), CD15-fluorescein isothiocyanate (BD Biosciences, clone HI98), CD16-PE (BD Biosciences, clone 3G8),
CD33-allophycocyanin (eBioscience, clone WM-53), CD3-V450
(eBioscience, clone OKT3), and CD19-PE (BD Biosciences, clone
HIB19). Defined hematopoietic cell populations that were sorted
included: promyelocytes (CD142, CD151, and CD16low/2),17
monocytes (CD141), neutrophils (CD142, CD151, and CD161),17
and CD341 cells. Cells were sorted directly into lysis buffer, and RNA
was isolated using the Quick-RNA Microprep Kit (Zymo Research).

Small RNA library construction and sequencing
The NEBNext Small RNA Library Prep Set for Illumina (New England
BioLabs, Inc.) was used to prepare the libraries following the
manufacturer’s specifications using 100 to 500 ng of total RNA as
152
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input.18 After adaptor ligation, reverse transcription, and polymerase
chain reaction (PCR) amplification, the libraries were size selected on
a Blue Pippin (Sage Science) to enrich for library molecules with
inserts between ;17 and 200 nucleotides. The resulting libraries
were sequenced on a MiSeq instrument to generate 150 bp, singleend reads. All sequence data will be deposited in dbGaP.

Bioinformatic analysis
Sequencing data were trimmed to remove adapter sequences using
cutadapt with the command “cutadapt -f fastq -a AGATCGGAAGAGCACACGTCT” and then mapped to the National Center for
Biotechnology Information Build 37 human reference sequence using
bwa mem19 with the custom parameters “bwa mem -M -k 15 -T 17” to
obtain short alignments that result from small RNA species. These
alignments were then used in the following analyses to characterize the
spectrum of RNA species captured by the library approach, identify
novel RNA species, and quantify the expression of annotated snoRNAs.
We first defined the distribution of RNA species captured in the
library by annotating the sequencing reads from all samples with RNA
biotypes from GENCODE version 19,20 mirBase version 21,21 and a
previously described set of snoRNA annotations (snoRNAome22).
Given that the library preparation method has a 39 end bias, reads
were assigned to a single RNA annotation in a strand-specific manner
based on the proximity of the read start position to the 39 end of
overlapping annotations. Reads were called “unannotated” if the
alignments were uncertain (ie, mapping quality of 0), or they did not
map to any annotation in a strand-dependent manner.
Next, we identified potentially novel RNA species using a custom
Practical Extraction and Report Language (PERL) script designed to
detect and annotate aggregate read “clusters” using pooled sequence data from all normal hematopoietic cell and AML samples
(N 5 64). Briefly, mapped reads for all samples with a mapping quality
.0 were merged into a single BAM file, and regions with a minimum
strand-specific read depth of 50 were extracted. All reads spanning
these regions were then merged to create strand-specific read
clusters, which were trimmed such that the cluster edges were $20%
of the maximum read depth (to separate closely spaced clusters that
may have become merged by spurious “joining” reads), and
subsequently filtered to retain those with an AT nucleotide content
,80% to exclude low-complexity sequences. The total number of
clusters that resulted from this procedure was 6231. Clusters were
then annotated with read quality and mapping statistics (eg, mean
mapping quality, number of unique read start positions, and mean
number of mismatches with the reference sequence), the number of
strand-specific read counts, and maximum depth across the cluster.
Cluster coordinates were compared with the GENCODE, mirBase,
and snoRNAome annotations, and “tagged” with the strand-specific
transcript or gene annotation with the best reciprocal overlap.
Potentially novel species from this set that demonstrated ,50%
reciprocal overlap with known annotations and total counts $500
(N 5 340 clusters) were then manually analyzed with the programs
snoGPS and snoSCAN, which identify H/ACA box and C/D box
snoRNAs with reported rRNA targets,23,24 and with snoReport for
identification of all snoRNAs, including orphans25 as well as a
custom script. This produced a final list of 111 clusters that were
identified as potential snoRNA species, which were manually
reviewed using the Integrated Genome Viewer (version 2.3.40)26
and the sno/miRNA track of UCSC Genome Browser27 to exclude
low-quality clusters or those that overlapped known snoRNAs.
23 JANUARY 2018 x VOLUME 2, NUMBER 2

Finally, expression levels for a comprehensive set of annotated sncRNA
species were generated for each sample using annotations curated
from snoRNAome22 and miRBase28 along with all GENCODE version
19 annotations with biotype “snoRNA.” These annotation databases
were combined to produce a set of 4931 nonoverlapping annotations,
with snoRNAome and mirBase entries superseding those from
GENCODE version 19 with overlapping coordinates. Overlapping
annotations from snoRNAome and mirBase were reviewed, and a
single species was selected based on the correspondence between
the sequencing reads at the locus and annotation; the other annotation
was excluded. Expression values for these annotations were then
obtained with the featureCounts program29 using parameters for
strand-specific counting and including only reads with a mapping
quality of $1. These counts were normalized to the total mapped reads
3 106 for visualization and subsequent statistical analyses.

Quantitative reverse transcription PCR of
selected snoRNAs
The extracted RNA was purified on a RNA Clean & Concentrator-5
column (Zymo Research, R1013) using the manufacturer’s .17nucleotide-long protocol and resuspended in 10.0 mL of nucleasefree water. The Qubit RNA HS Assay Kit (Life Technologies,
Q32855) and the TapeStation system (Agilent) were used for
quantification and quality assessment, respectively, according to the
manufacturer’s instructions. The RNA was reverse transcribed using
iScript Reverse Transcriptase (BioRad, 1708841) at 42°C, according to the manufacturer’s instructions. The complementary DNA
(cDNA) was PCR amplified using forward and reverse primers
containing sequences specific to the snoRNAs (supplemental
Table 1). In a 20-mL reaction, 3.0 ng of cDNA template, 0.5 mM
each of forward and reverse primers (IDT), 10 mL iTaq Universal
SYBR Green 23 Supermix, (BioRad, 1725120), and nuclease-free
water were cycled for 60 rounds at an annealing temperature of 60°C
on a StepOnePlus Real-Time PCR System (Applied Biosystems).
The 5S rRNA was used to normalize snoRNA expression.

Differential expression analysis
Differential expression and hierarchical clustering analyses were
performed with the Partek Genomic Suite (Partek, Inc.) using log2
(read count per million mapped reads 3 106 [RPM]) expression
values for the curated sncRNA annotations as input30; only RNA
species with mean normalized count values $5 were selected to
produce reliable differential expression profiles. Data were first
assessed for normality, and differential expression analysis was
performed with the Partek Genomic Suite using 1-way analysis of
variance (ANOVA) with estimation via the method of moments
model.31 The differential expression of snoRNAs and miRNAs in the
AML patients vs normal hematopoietic stem/progenitors was based
on a fold change .2 and P , .05).

Splicing analysis
Intron junction counts for annotations in GENCODE version 19
were obtained from aligned BAM files using Tablemaker and
Ballgown32 and normalized to the total number of junction reads
observed 3 106. The linear regression between normalized
snoRNA expression (RPM) and the normalized expression for “host
gene” junctions spanning each snoRNA were assembled in R.33
Correlations between all snoRNAs and junction expressions were
similarly performed.
23 JANUARY 2018 x VOLUME 2, NUMBER 2

Somatic mutation of snoRNAs
The coordinates of the 344 651 introns in the genome (GRCh37)
and that of 402 snoRNAs were intersected with the coordinates of
367 904 prevalidation indels from 49 Cancer Genome Atlas AML
patient samples using BEDtools34 and R.

Statistical analysis
Statistical analysis and graphing were performed with Prism
(GraphPad Software, Inc.) and R. Error bars represent the standard
error of the mean (SEM). Significance was determined by 1-way
ANOVA followed by Tukey multiple comparisons test. Significance
is denoted as: *P , .05; ** , .01; ***P , .001; ****P , .0001; and
ns, not significant.

Results
Small RNA-seq pipeline
We modified a previously described method for sequencing
miRNAs to analyze more comprehensively the small RNA component of the transcriptome.18 A key aspect of this approach is the
method used for cDNA library generation, which includes the
addition of an oligonucleotide adaptor to the 39-end of RNA
molecules before reverse transcription. Importantly, this requires the
presence of a free 39 hydroxyl group on the RNA molecule. We then
performed an expanded size selection to capture RNA species
between 17 and 200 nucleotides, which includes miRNAs,
snoRNAs, and other sncRNAs, but excludes most messenger
RNA (mRNA) and lncRNA molecules. The sequence data obtained
were analyzed using 2 complementary bioinformatic approaches to
quantify both annotated and novel sno- and miRNAs (Figure 1A).
We used this approach to interrogate the small RNA transcriptome
in human hematopoietic cell populations from normal hematopoietic
stem/progenitors and from diagnostic AML samples. CD34 cells,
promyelocytes, neutrophils, monocytes, T cells, and B cells were
sorted by flow cytometry from the bone marrow of 6 healthy
individuals. Data from primary AML samples were generated from
bulk leukemic cells from 33 treatment-naive patients with AML
(Table 1). Most of these cases (97%) had normal cytogenetics, and
all were classified as intermediate-risk AML. An average of 3.2 3
106 reads was obtained across both normal and leukemic samples
(supplemental Table 2). Mapping of sequencing reads from all
samples to annotation features from GENCODE version 19 and
snoRNA and miRNA annotations in the human snoRNAome and
miRBase (see “Materials and methods”) demonstrated that
snoRNAs were by far the most abundant small RNA species
present in our data (Figure 1B). C/D box snoRNAs represented
74.95% of all reads; H/ACA box snoRNAs and scaRNAs
represented another 3.19% and 0.34% of total mapped reads,
respectively. Small nuclear RNAs, which are involved in RNA
splicing, were the next most abundant class of sncRNA, representing 10.19% of reads. miRNAs represented a relatively small
percentage of all sequenced reads (1.48% of all mapped reads).
Reads mapping to unannotated regions of the genome accounted
for 0.04% of all sequences.
We next compared the expression of snoRNAs using data from our
modified library protocol with expression levels obtained by
standard total RNA sequencing (RNA-seq) (Illumina Tru-seq) and
of the same tissue sample. Relevant to this analysis, the majority of
snoRNAs are embedded in the introns of host genes. We observed
snoRNA EXPRESSION IN NORMAL HEMATOPOIESIS AND AML
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Figure 1. Small RNA-Seq pipeline. (A) Schematic representation of the small RNA-seq pipeline. Sequence reads were aligned to the GENCODE version 19, miRBase
version 21, and human snoRNAome, and reads corresponding to annotated sncRNAs were quantified (left pathway). Alternatively, aligned sequence reads were organized
into genomic clusters; a total of 111 unannotated clusters were identified, of which 8 were classified as novel snoRNAs (right pathway). (B) Graph showing the distribution of
annotation biotypes in GENCODE version 19 for mapped reads from all samples. The percentage of all mapped reads (mapping quality .0) is shown on the y-axis, and the
annotated species is shown on the x-axis. Miscellaneous (Misc) snoRNAs include rRNAs, other species include unprocessed pseudogenes, immunoglobulin genes, T-cell
receptor genes, sense introns, antisense transcripts, sense overlapping transcripts, retained introns, and processed transcripts. Protein-coding genes include nonsense
mediated decay, and nonstop decay biotypes. (C) Integrated Genome Viewer browser view of SNORA64, which is embedded in an intron of the coding gene RPS2. The top
panel shows the alignment of reads generated using total RNA-seq. The middle panel shows the alignment of reads from a small RNA-seq library produced from the same
sample. The genomic boundaries of SNORA64 and exons 4 and 5 of host gene RPS2 are shown in the bottom panel. (D) Representative scatter plot showing log-transformed
normalized read counts of annotated snoRNAs for a CD34 sample analyzed using total RNA-seq (y-axis) or our small RNA-seq pipeline (x-axis).

that standard transcriptome sequencing cannot reliably distinguish
unspliced primary host gene RNA from correctly processed
snoRNA. Typical results are shown for SNORA64, which is located
in the intron of its host gene, RP32 (Figure 1C). Whereas sequence
reads corresponding to mature SNOR64 were readily identified
using our pipeline, only low-level reads that span the entire intron
of RP32 were detected using total RNA-seq. Accordingly, the
correlation of snoRNAs quantified using these 2 RNA-seq pipelines
was poor (Figure 1D). These data demonstrate the superiority of our
small sequencing pipeline to quantify mature, correctly processed
snoRNA expression.
To provide orthogonal validation of the snoRNA expression data, we
used commercially available reagents to perform quantitative reverse
154

WARNER et al

transcription PCR (RT-qPCR) on a set of 9 snoRNAs with a wide
range of expression across 11 primary AML samples. Although some
variability was observed, a significant correlation between snoRNA
expression determined by small RNA Seq and RT-qPCR was
observed (R2 5 0.5002; P , .0001; supplemental Figure 1).
To determine whether our sequencing approach identified any
novel RNA species, we formed read clusters by merging overlapping reads and compared them with the RNA annotations as
described above. The intersection of read cluster coordinates with
our sncRNA annotation set demonstrated that a number of them did
not overlap with known annotations, and could therefore represent
novel RNA species. The genomic regions spanned by these
clusters were then analyzed for features of snoRNAs, including the
23 JANUARY 2018 x VOLUME 2, NUMBER 2

Table 1. Characteristics of the 33 AML patients
Characteristic

Value

Age at study entry, mean 6 standard deviation, y

51.3 6 15.0

Race or ethnic group, n (%)
White

26 (78.8)

African American

1 (3.03)

Other

6 (18.18)

Male sex, n (%)

14 (42.4)

Bone marrow blasts at diagnosis, mean 6 standard
deviation, %
Normal cytogenetic profile, n (%)

81.8 6 13.4
32 (97)

White blood cell count at diagnosis, 310 /L
9

Mean 6 standard deviation

63.66 6 70.75

Median

45.60

Cytogenetic risk group, n (%)
Intermediate

33 (100.0)

AML FAB subtype, n (%)
AML without maturation: M1

18 (54.5)

AML with maturation: M2

1 (3.03)

Acute myelomonocytic leukemia: M4

5 (15.1)

Acute monoblastic or monocytic leukemia: M5

9 (27.3)

Mutation, n (%)
NPM1

27 (88.8)

FLT3

18 (54.5)

DNMT3A

12 (36.4)

IDH1 or IDH2

10 (30.3)

NRAS or KRAS

4 (12.1)

CEBPA

3 (9.1)

TET2

2 (6.1)

WT1

2 (6.1)

PTPN11

2 (6.1)

FAB, French-American-British.

presence of conserved sequence motifs and secondary structure.
Eight putative novel snoRNAs were identified, including 5 in the
SNORA family and 3 in the SNORD family. One of the putative
SNORDs lacked sequence complementarity to rRNAs or snRNAs
and was therefore classified as an orphan snoRNA (supplemental
Table 3). There was some degree of overlap (#50%) with
annotated species, but our analysis supports the characterization
of these snoRNAs as putatively novel.

Developmental- and lineage-specific expression of
snoRNAs in human hematopoiesis
Because snoRNAs were the most abundant sncRNA detected, we
focused our analysis on these RNA species. We first performed
unsupervised hierarchical clustering of annotated snoRNAs with a
normalized expression of $5 RPM (N 5 378) to determine whether
expression of snoRNAs is developmentally regulated during hematopoiesis. This demonstrated that snoRNAs exhibit lineage- and developmentally restricted expression patterns (Figure 2). The most
striking examples were orphan snoRNAs contained in the imprinted
DLK-DIO3 and SNURF/SNRPN loci. The DLK-DIO3 locus contained
23 JANUARY 2018 x VOLUME 2, NUMBER 2

a large number of maternally expressed ncRNAs, including 41
snoRNAs, 11 lncRNAs, and 53 miRNAs (Figure 3A). Expression of
snoRNAs in this locus was highest in CD34 cells and rapidly decreased
with granulocytic differentiation, becoming nearly undetectable in
mature neutrophils (Figure 3B). Expression of these snoRNAs was
also markedly reduced in B cells and T cells. Expression of snoRNAs in
the SNURF/SNRPN locus showed a similar, but distinct, pattern of
snoRNA expression. This locus contained 82 paternally expressed
snoRNAs that were expressed at a high level in CD34 cells and rapidly
downregulated during granulocytic differentiation (Figure 3C). However, in contrast to the DLK-DIO3 locus snoRNAs, expression of these
snoRNAs remained high in B and T cells (Figure 3D).

Expression of a subset of snoRNAs is decreased
in AML
We next compared snoRNA expression in 33 de novo AML samples
with normal CD34 cells. Analysis of expression across all annotated
snoRNA species (N 5 364) via unsupervised hierarchical clustering
demonstrated that AMLs had distinct snoRNA expression patterns from
normal CD34 cells (Figure 4A). We required a mean normalized
expression of $5 counts across any AML and healthy donor samples to
be considered for analysis. Differential expression analysis identified 102
snoRNAs that were differentially expressed (adjusted P # .05; absolute
log2-fold change . 1) (supplemental Table 4), all of which had
decreased expression in the AML samples (Figure 4B). By comparison,
24 differentially expressed miRNAs were identified in a similar analysis
using the same samples, which included 17 with increased expression
in AML vs 7 that were decreased (Figure 4C). Although differentially
expressed snoRNAs in AML spanned all RNA species, a disproportionate number of box C/D snoRNAs were observed (69 of 102,
67.65%; Figure 4D), with 37 located in the DLK-DIO3 or SNURFSNRPN loci. There were 66 (64.71%) orphan snoRNAs with
representation from all snoRNA classes. Of note, differential expression
of snoRNAs that are known to play key roles in splicing as well as the
modification of the peptidyl transferase center (PTC) and the
intersubunit bridge (ISB) during ribosomal biogenesis was observed
(supplemental Table 4). For example, expression of SNORA21 and
-36C, which target crucial nucleotides in the PTC and ISB, respectively,
were decreased 2.69- and 2.56-fold, respectively, in AML compared
with CD34 cells, and expression of SCARNA15, which targets a key
nucleotide in the U2 spliceosomal RNA, was decreased 2.81-fold.

Somatic mutation of snoRNAs is uncommon in AML
Whole-genome sequencing data were available for 14 of the 33
analyzed cases in this study. No somatic single nucleotide variants or
small indels were detected in the snoRNA genes. In addition, for those
snoRNAs located in a host gene, no recurrent indels in the introns
harboring the snoRNA or mutations in splice donor sites for that intron
were identified. We expanded this analysis to an additional 35 AML
cases with whole-genome sequencing data available from the The
Cancer Genome Atlas.35 Again, no somatic single nucleotide variants or
small indels were detected in snoRNA genes, suggesting that genetic
alterations in snoRNAs are uncommon in AML with normal cytogenetics
and are not the cause of their differential expression in this disease.

There is minimal correlation between host gene and
snoRNA expression
Because many snoRNAs are located in the introns of host genes,36
we next asked whether variation in snoRNA expression may be
snoRNA EXPRESSION IN NORMAL HEMATOPOIESIS AND AML
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Figure 2. Unsupervised hierarchical clustering of snoRNA expression. Small RNA-seq was performed on the indicated sorted hematopoietic cell populations obtained
from 4-6 normal hematopoietic stem/progenitors. snoRNA expression (z-scored log2 RPM) is shown, with red indicating high expression, and green indicating low expression.
Each column represents a unique snoRNA, and each row represents a sample.

explained by differences in expression and/or processing of these
host genes. We limited our analysis to the AML cases, where
matching small RNA and total RNA-seq data were available. For most
snoRNAs, there was minimal correlation between host gene and
corresponding snoRNA expression, as illustrated by host gene
RPL7A and its corresponding snoRNAs (Figure 5A). Across all 1379
snoRNAs contained in host genes, the average coefficient of
determination (R2) was 0.037 6 0.102 (Figure 5B). Multiple
snoRNAs are often located within different introns of a single host
gene, as shown for the C19orf48 gene (Figure 5C). If host gene
expression is the primary determinant of snoRNA expression, then
expression of each snoRNA located in a given multihost gene should
be similar. However, we observed marked variability in the expression
of snoRNAs contained within a single gene. For example, expression
of the 3 snoRNAs hosted by C19orf48 varied by .32-fold
(Figure 5D). Indeed, marked variability in the expression of snoRNAs
contained within the same host gene was observed in the majority of
cases (Figure 5E). These data show that host gene expression is not
the primary determinant of snoRNA expression in AML.

Alternative splicing of host genes is not the primary
determinant of snoRNA expression
Mature snoRNAs are processed from excised introns after splicing of
the host gene. Thus, we next asked whether alternative splicing of host
genes is a major determinant of snoRNA expression. We assessed
RNA splicing by measuring junction reads, as previously described.37
For example, the host gene C19orf48 has 10 predicted splice events
156
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that involve introns containing embedded snoRNAs (Figure 6A).
Expression of junction reads corresponding to each splice event
showed minimal correlation with expression of the relevant snoRNA
(Figure 6B-K). This analysis was extended to look at snoRNA
expression and encompassing junction expression across 858
snoRNAs spanning 1616 junctions (Figure 6L). For most cases,
junction reads correlated minimally with snoRNA expression. Collectively, these data show that alternative splicing of host genes is unlikely
to be the primary determinant of snoRNA expression.

Discussion
The expression of snoRNAs has traditionally been determined by
high-throughput techniques that rely on hybridization-based methods, such as microarray analysis or by standard RNA-seq
technologies.12-14 Microarrays for snoRNAs are unable to effectively capture novel sequences or resolve the expression of
snoRNAs in families with highly homologous members.38 Standard
RNA-seq is generally limited to RNA species .200 nucleotides in
length, and thus does not reliably detect most sncRNAs, including
snoRNAs. In this study, we optimized both library preparation and
bioinformatic analysis to address these challenges, which resulted
in improved sensitivity for detecting novel sncRNAs, more accurate
expression levels of annotated species, and efficient resolution of
closely related snoRNA species, such as those in the DLK-DIO3
and SNURF-SNRPN loci. In addition, for those snoRNAs embedded in host genes, this approach can distinguish between host
gene primary transcripts and mature, fully processed snoRNAs.
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Figure 3. Expression of snoRNAs in the DLK-DIO3 and SNURF/SNRPN loci. (A) Organization of the DLK-DIO3 locus. Maternally expressed genes (open boxes)
and paternally expressed genes (filled boxes) are shown. The miRNA cluster contains 54 miRNAs. (B) Normalized read counts for SNORD113-6 are shown;
its expression is representative of other SNORDs in this locus. Significance was determined by 1-way ANOVA followed by Tukey multiple comparisons test.
(C) Organization of the human SNURF-SNRPN locus (drawing is not to scale). Paternally expressed genes, including SNORDs, are shown as n, and maternally
expressed genes are shown as N. (D) Normalized read counts for SNORD116-1, representative of SNORDs in the SNURF-SNRPN locus, are shown.
****P , .0001. ns, not significant.

The best method to normalize small RNA-seq expression data is
uncertain. For miRNAs, several studies have compared normalization
methods, suggesting that the upper quartile, median, the DESeq
normalization offered in the DESeq Bioconductor package, and the
trimmed mean of M values offered in the edgeR Bioconductor package
may be superior to the RPM normalization method.39-41 In the absence
of a “gold standard” for snoRNA expression, a rigorous comparison of
normalization strategies of our small RNA-seq snoRNA expression data
was not possible. Thus, in this study, we normalized our small RNA-seq
data with the widely used RPM method.
To our knowledge is the first study to comprehensively analyze
snoRNA expression in human hematopoiesis. snoRNAs are the most
highly expressed sncRNAs in all of the hematopoietic cell populations
tested. Although snoRNAs have been considered to be housekeeping genes,42 we identified a subset of snoRNAs that exhibit marked
differential expression in a lineage- and development-specific pattern.
This is particularly true for orphan snoRNAs contained in the
imprinted DLK-DIO3 and SNURF/SNRPN loci. The DLK-DIO3
23 JANUARY 2018 x VOLUME 2, NUMBER 2

locus contains 47 orphan CD box snoRNAs that are highly
expressed in CD34 cells and downregulated during myeloid or
lymphoid differentiation. This observation is consistent with
previous reports showing high hematopoietic stem/progenitor
expression of lncRNAs43 and miRNAs44 that are contained in the
DLK-DIO3 locus. The SNURF/SNRPN locus contains 2 large
orphan CD box snoRNA clusters, SNORD115 and SNORD116,
that are expressed highly in CD34 cells and downregulated during
myeloid differentiation. Loss of SNORD116 in the SNURF/
SNRPN locus is thought to be key to the pathogenesis of
Prader-Willi syndrome, a genetic disorder characterized by
obesity and developmental delay.45,46 Of note, SNORD115 has
been shown to promote alternative splicing of the serotonin
receptor 2C.47 The contribution of the DLK-DIO3 and SNURF/
SNRPN loci to hematopoietic stem/progenitor function is unknown, although it is interesting to note that expression of ncRNAs
from the DLK-DIO3 locus correlates with pluripotency in both
embryonic and inducible pluripotent stem cells.48
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We observed no recurring mutations of snoRNA genes in our cohort
of cytogenetically normal AML, suggesting that genetic alterations
that specifically target snoRNAs in AML are uncommon. A previous
study reported that snoRNAs are globally suppressed in AML relative
to CD34 cells from normal hematopoietic stem/progenitors.14
Although we also observed a trend toward decreased expression
in AML, this was limited to a small subset of snoRNAs (102 of 364,
28%). The reasons for this discrepancy are not certain, but the
previous study primarily used a microarray approach to assess

expression of a more limited set of snoRNAs. Of note, of the 102
snoRNAs with significantly reduced expression in AML, 37 are
located in the DLK-DIO3 or SNURF-SNRPN loci. Because
expression of these snoRNAs is suppressed during normal myeloid
differentiation, it is possible that their decrease in AML reflects normal
differentiation along the myeloid lineage. This is in sharp contrast to
previous studies showing marked increased expression of DLK-DIO3
snoRNAs in acute promyelocytic leukemia.12-14 Of note, Valleron et al
showed that enforced expression of SNORD114-1, which is

Figure 4. (continued) represent the threshold for the log2 fold change (equivalent to a twofold difference). The y-axis reflects the 2log10 (q value–corrected P value). Green
and red colored dots represent snoRNAs showing significantly increased or decreased expression in AML, respectively. (D) Distribution of differentially expressed snoRNAs
across snoRNA subtypes. H/ACA snoRNA distribution includes 4 AluACA snoRNAs.
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contained in the DLK1-DIO3 locus, promotes cell growth in vitro,
possibly by targeting the Rb pathway.14
We observed significant differential expression of snoRNAs that
mediate pseudouridylation or 29-O methylation of key sites in rRNA.
Decreased expression of snoRNAs that target modifications of
the PTC and ISB regions of the 60S ribosome was observed in
AML patients vs normal hematopoietic stem/progenitors. The PTC is
the catalytic site where peptide bonds are made during protein
elongation and peptidyl-tRNAs are hydrolyzed during the termination
of protein synthesis.49 The ISB forms multiple interactions between
the ribosomal subunits, which maintain ribosome stability and
modulate dynamics that are critical for translation, such as that
between the tRNA and mRNA.50 Studies in yeast suggest that,
although loss of pseudouridylation or 29-O methylation at individual
rRNA sites has only subtle effects on activity, loss at multiple sites is
synergistic, resulting in reading frame changes, increased stopcodon read-through, and altered tRNA selection.51-53 We also
identified several snoRNAs responsible for the pseudouridylation of
snRNAs in regions critical for splicing. For example, scaRNA15,
whose expression is reduced 2.81-fold in AML, targets the branch
site recognition region of U2 snRNA. Studies in HeLa cells54 and
yeast55 show that pseudouridylation at this site is required for the
formation of early spliceosomal complexes and the catalytic phase of
pre-mRNA splicing. Further study is needed to determine whether the
observed decreases in snoRNA expression in AML are sufficient to
induce biologically meaningful differences in translation or splicing.
The mechanisms regulating snoRNA expression are not well defined.
Most snoRNAs and scaRNAs are embedded in the introns of host
genes that produce proteins involved in nucleolar function, ribosome
structure, or protein synthesis,56 providing a potential mechanism for
the coordinated expression of snoRNAs and proteins targeting
common pathways. Interestingly, we observed that in AML, snoRNA
expression correlates minimally with host gene expression. Recent
studies in yeast and human brain samples have reported a similar
uncoupling of host gene and snoRNA expression.57-59 Indeed, we
even observed striking variability in the expression of snoRNAs
contained in the same host gene. Mature snoRNAs are produced
from host genes by exonucleolytic processing of the debranched intron
after splicing.60,61 A recent study suggested that alternative splicing of
host genes contributes to the regulation of snoRNA expression and
accounts, in part, for the variability in the expression of snoRNAs
contained with the same host gene.62 However, in AML, snoRNA
expression and alternative splicing correlate minimally. Thus, in AML,
other mechanisms besides host gene expression or splicing are
contributing to mature snoRNA expression. This may include
alterations in snoRNA processing, secondary snoRNA structure
stability, maturation, trans-acting protein accumulation factors, and
intranuclear trafficking of the maturing snoRNPs to the nucleolus or
Cajal body.63 Of note, many snoRNA host genes contain a
characteristic terminal oligopyrimidine track in their 59-untranslated
region that has been shown to modulate the differential production of

mRNA vs snoRNAs from that host gene.64,65 Given the critical role of
snoRNAs in translation, the contribution of these various elements to
the regulation of snoRNA expression warrants further study.
As outlined, array-based and qPCR-based approaches do not
distinguish between mature snoRNAs and primary mRNA transcripts
containing unprocessed snoRNAs. Without robust orthogonal validation
technologies for generating gold standard expression values, optimal
statistical procedures for expression normalization from count-based
sequence data have not been established for snoRNAs. This contrasts
with miRNA squencing data, for which qPCR provides robust
orthogonal validation that has made it possible to evaluate and optimize
expression normalization methods.40 In the absence of a consensus
approach for snoRNA data, we used the total count method, which
involves normalization of the read count for each snoRNA species for the
total number of counts obtained for each experiment. Additional studies
will be needed to determine the optimal normalization procedures for
sequence data from this intermediate-sized RNA species.
In summary, we developed a small RNA-seq pipeline to quantify
snoRNA and other sncRNA expression. We showed that a subset of
snoRNAs are regulated in lineage- and development-specific expression. Although genetic alterations that specifically target snoRNA genes
in AML appear to be uncommon, a subset of snoRNAs are differentially
expressed. The contribution of these differentially expressed snoRNAs
to the regulation of normal and malignant hematopoiesis represents an
exciting new area of investigation.
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